FDA Criticized Novo Nordisk Over Wegovy Advertising
The health agency sent two letters to the drugmaker regarding its television and digital video promotional campaigns.
Updated on Sept. 30, 2026 in Weight Loss
Live Poll
Do you trust marketing campaigns for prescription drugs to provide an accurate picture of medical treatments?
The FDA issued untitled letters to Novo Nordisk in February 2026 concerning television and video advertisements for its Wegovy and Ozempic weight-loss products. The letters follow aggressive direct-to-consumer marketing strategies amid declining insurance coverage for obesity treatments.
Why it matters
As employers and health plans narrow insurance coverage for weight-loss drugs, manufacturers are increasingly targeting individual consumers directly through telehealth visits and self-pay channels to maintain demand.
Clinical trials for Wegovy demonstrated a 13.6 percent average weight loss among all participants, rising to 17 percent for those who completed the full treatment regimen.
The players
Novo Nordisk
This global pharmaceutical company specializes in diabetes care, obesity treatments, and other chronic health conditions.
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of drugs and medical devices.
The details
Novo Nordisk, which refers to its medication users as customers, utilized marketing slogans including "Live lighter" and "Summer Glow Up." Direct-to-consumer sales, which bypass insurance prior authorization requirements, now account for 50 percent of total Wegovy business and 90 percent of demand for its pill version.
Timeline
January 2026: A television advertisement for Wegovy aired.
February 5, 2026: The FDA issued an untitled letter regarding a television advertisement.
February 26, 2026: The FDA issued a second untitled letter regarding an Ozempic video advertisement.
Health Landscape
This enforcement action aligns with the FDA's long-standing regulations on prescription drug advertising, which mandate that promotional materials accurately reflect product risks and benefits. It highlights the tension between pharmaceutical marketing practices and federal oversight as direct-to-consumer spending grows.
Patients may notice changes in how weight-loss treatments are marketed as companies adjust their messaging to comply with federal standards. Consumers should remain aware that direct-to-consumer marketing strategies often bypass traditional insurance verification processes, which may affect out-of-pocket costs.
The takeaway
The rise of direct-to-consumer medical marketing underscores the importance of verifying treatment benefits through clinical evidence rather than television slogans. Patients are encouraged to consult with healthcare providers before initiating weight-loss therapies, regardless of marketing claims.
Further reading
For more information on the evolving landscape of obesity medications, visit the Weight Loss section.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you trust marketing campaigns for prescription drugs to provide an accurate picture of medical treatments?
